Dynorphin A (1-8): natural pain-signaling brain peptide
A small fragment of the body's own opioid peptide dynorphin, found in humans and other mammals; acts on the same receptors as morphine to help regulate pain and mood. Used only as a lab research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Dynorphin A (1-8) is the eight-amino-acid N-terminal fragment of Dynorphin A, an endogenous opioid neuropeptide produced from the preprodynorphin precursor. Its sequence — YGGFLRRI — opens with the classical opioid "message" tetrapeptide YGGF that is shared across enkephalins, endorphins, and the dynorphins, followed by a short basic "address" LRRI that distinguishes the dynorphin family. In the body, longer dynorphin peptides are cleaved by proprotein convertases into smaller fragments like this one, and the resulting peptides circulate within the central and peripheral opioid signaling system that controls pain, mood, and gut motility (Sobczak 2014; Pasternak 2013).
The peptide has been observed directly in tissue. Petruzziello and colleagues (2012), in a mass-spectrometric survey of the Tupaia belangeri (tree shrew) neuropeptidome, catalogued dynorphin-family peptides — including fragments and intermediates — as products of preprodynorphin processing, alongside α-neoendorphin and the longer Dynorphin A and Dynorphin B forms.
History
The dynorphin peptides were first isolated and named in the late 1970s as exceptionally potent opioid peptides from the pituitary, and the full preprodynorphin precursor was subsequently cloned. The Dynorphin A (1-8) fragment emerged in this period as a recognised endogenous processing product of the precursor, distinct from the longer Dynorphin A (1-17). The broader opioid-receptor framework these peptides act through took its modern shape over the following two decades, including the functional cloning of the δ-opioid receptor by Evans and colleagues (1992) and the long pharmacology of µ-opioid receptors and their endogenous ligands reviewed by Pasternak and colleagues (2013).
What it does
Dynorphin A (1-8) is a member of the opioid peptide family — the class of small endogenous peptides that modulate pain perception, reward, mood, stress responses, and gastrointestinal function by binding to opioid receptors (Pasternak 2013; Valentino 2018). Like other dynorphin-family peptides, its signature N-terminal Tyr-Gly-Gly-Phe motif is the structural feature that lets it engage opioid receptors at all; the C-terminal residues then modulate which receptor subtype and which downstream behavior dominates (Valentino 2018).
The longer parent peptides in this family are best known for activity at the kappa-opioid receptor and for roles in dysphoria, stress, and analgesia (Ko 2020), while the broader opioid system also engages µ- and δ-receptors with distinct behavioral profiles (Pasternak 2013; Valentino 2018). Where the (1-8) fragment specifically sits within that landscape is more nuanced than the full-length peptide: shortening Dynorphin A from 17 to 8 residues strips off most of the "address" region, so receptor preference and potency for the fragment do not simply mirror the parent. The dossier sources do not pin a single, definitive receptor profile to Dynorphin A (1-8) on their own.
Beyond classical analgesia, dynorphin peptides have also been examined as candidate modulators in epilepsy and seizure circuitry — Clynen and colleagues (2014) reviewed dynorphins among the neuropeptides considered as targets for anticonvulsant drug development — and the opioid system more broadly is a major regulator of gastrointestinal motility, secretion, and visceral pain (Sobczak 2014).
Evidence
- Human: No human clinical trials of Dynorphin A (1-8) appear in this dossier; the supporting literature here is review-level rather than interventional.
- Animal / preclinical: Indirect — the peptide is discussed within reviews of opioid-receptor pharmacology and gastrointestinal opioid signaling (Sobczak 2014; Pasternak 2013) and within reviews of neuropeptides as anticonvulsant targets (Clynen 2014). Non-human-primate kappa-opioid ligand pharmacology — relevant context for the dynorphin family but not specific to the (1-8) fragment — is reviewed in Ko (2020).
- In vitro / detection: Documented as a processing product of preprodynorphin in a tree-shrew neuropeptidome characterized by mass spectrometry (Petruzziello 2012). The opioid-receptor family that this peptide engages has been characterized through decades of cloning and pharmacology work, beginning with the functional cloning of the δ-opioid receptor (Evans 1992) and the broader evolutionary picture of vertebrate opioid receptors (Stevens 2009).
Known effects
The effects below describe the dynorphin / opioid-peptide system in general — the dossier does not isolate (1-8)-specific outcomes from those of the parent peptides.
- Pain modulation — Mechanistic, reviewed within opioid receptor pharmacology (Pasternak 2013; Valentino 2018)
- Gastrointestinal motility and secretion — Reviewed for opioid receptors and their ligands in the GI tract (Sobczak 2014)
- Seizure / anticonvulsant relevance — Mechanistic, dynorphin family discussed among neuropeptide targets (Clynen 2014)
- Kappa-opioid-related behavioral effects (dysphoria, stress, antinociception) — Documented for kappa-opioid ligands in non-human primates; family-level rather than fragment-specific (Ko 2020)
Safety signals
The dossier does not contain trial-derived safety data for Dynorphin A (1-8). Opioid peptides as a class engage receptors that overlap pharmacologically with clinically used opioid drugs, and the kappa-opioid arm of that system in particular is associated with dysphoria and stress-like effects in animal models (Ko 2020). No specific adverse-event profile for the (1-8) fragment is reported in the sources collected here.
Sequence note
The platform sequence is YGGFLRRI (8 residues) — the N-terminal eight amino acids of Dynorphin A (1-17), whose full sequence is YGGFLRRIRPKLKWDNQ as catalogued in the neuropeptide tables of Clynen and colleagues (2014). The "YGGF" prefix is the conserved opioid message motif shared with the enkephalins, β-endorphin, and the other dynorphin peptides; "LRRI" is the start of the dynorphin-specific address segment, with the dibasic Arg-Arg providing a recognised proprotein-convertase cleavage context that generates short fragments like this one from the longer precursor (Petruzziello 2012). The raw sequence shown here has free N- and C-termini and no further chemical modification documented in the dossier.
Related peptides
- The parent peptide — full-length Dynorphin A (1-17) — and Dynorphin B / α-neoendorphin are catalogued as the principal preprodynorphin products in the same neuropeptidome surveys (Petruzziello 2012).
- The shared opioid "message" tetrapeptide YGGF places this fragment in the same broad family as the enkephalins (Met-enkephalin YGGFM, Leu-enkephalin YGGFL) and β-endorphin (Clynen 2014).
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could the protein that chops dynorphin into its shortest form be the hidden dial that controls whether stress or morphine-like pain relief dominates in the nervous system?
If one enzyme controls which opioid receptor gets activated by shifting the ratio of dynorphin forms, blocking or enhancing that enzyme could tune pain relief circuits without directly touching opioid receptors, potentially offering a way to treat chronic pain or opioid withdrawal with a new class of drugs.
If the shortest dynorphin fragment were chemically bent into a small ring, would it resist the body's digestive enzymes while still working on the opioid receptor?
Natural peptides are quickly destroyed in the body, preventing them from being used as drugs. Stable ring-shaped analogs could be taken as medicines that last long enough to provide pain relief, potentially forming the basis of non-addictive opioid drugs derived from the body's own chemistry.
Does the last building block of the shortest dynorphin act like a molecular key that fits uniquely into the mu opioid receptor and not the others?
Knowing exactly which part of a peptide confers receptor specificity is a powerful design tool. If confirmed, medicinal chemists could attach similar hydrophobic groups to other opioid scaffolds to engineer highly selective mu-receptor drugs with reduced off-target effects.
Is the smallest natural form of dynorphin actually a better match for the main opioid pain receptor than the full-length version?
If the 8-residue fragment is the best mu-receptor binder, it could be developed into a compact, potentially safer painkiller that is easier and cheaper to manufacture than full-length dynorphin or synthetic opioids, with a more predictable receptor profile.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.9415448307991028 | boltz-2 |
| ranking score | 0.8403124213218689 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.659 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep10699,
sequence = {YGGFLRRI},
target = {oprm1},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}